top of page
Brunie Felding

Brunie H. Felding, PhD

Chief Scientific Officer
Biology and Biochemistry

  • LinkedIn
Brunie Bio


Dr. Brunie H. Felding, Ph.D., is a distinguished scientist renowned for her contributions to cancer biology and immunotherapy. She completed her B.S. and M.S. in Biology and Developmental Physiology from Justus Liebig University in Giessen, Germany, and earned her Ph.D. in Biochemistry from Justus Liebig University Giessen and Philipps University Marburg, Germany, graduating summa cum laude. Her pioneering research on cancer metastasis during her doctoral studies has been instrumental in understanding the molecular mechanisms driving tumor progression and resistance.

Dr. Felding's career is marked by numerous prestigious positions at leading research institutions. From 1984 to 1987, she was a Research Associate at Philipps University Marburg, Germany, followed by a Research Associate role with Dr. S. Hakomori at Fred Hutchinson Cancer Research Center and The Biomembrane Institute in Seattle, WA, from 1987 to 1989. She then served as an External Principal Investigator at E. Merck KG in Darmstadt, Germany, and a Visiting Scientist at The Scripps Research Institute in La Jolla, CA. She led the Cell Adhesion Research Group at E. Merck KG from 1991 to 1993, and subsequently held positions at The Scripps Research Institute, progressing from Senior Research Associate to Associate Professor with Tenure from 1993 to the present.

Dr. Felding recently joined CureScience Institute as the Chief Scientific Officer, bringing her passion for scientific discovery and commitment to improving patient outcomes. She is enthusiastic about the institute's mission and is dedicated to driving forward its research programs. With her leadership, CureScience aims to make groundbreaking advancements in healthcare, ultimately working towards curing diseases and enhancing the quality of life for patients worldwide.

Most Recent Publications

1) Takada YK, Shimoda M, Maverakis E, Felding BH, Cheng RH, Takada Y. Soluble CD40L activates soluble and
cell-surface integrin αvβ3, α5β1, and α4β1 by binding to the allosteric ligand-binding site (site 2). J Biol
Chem. 2021 Jan-Jun;296:100399. doi: 10.1016/j.jbc.2021.100399. Epub 2021 Feb 9. PubMed PMID: 33571526;
PubMed Central PMCID: PMC7960543.

2) Johnson CH, Santidrian AF, LeBoeuf SE, Kurczy ME, Rattray NJW, Rattray Z, Warth B, Ritland M, Hoang LT,
Loriot C, Higa J, Hansen JE, Felding BH, Siuzdak G. Metabolomics guided pathway analysis reveals link between
cancer metastasis, cholesterol sulfate, and phospholipids. Cancer Metab. 2017;5:9. doi: 10.1186/s40170-017-
0171-2. eCollection 2017. PubMed PMID: 29093815; PubMed Central PMCID: PMC5663111.

3) Roy S, Axup JY, Forsyth JS, Goswami RK, Hutchins BM, Bajuri KM, Kazane SA, Smider VV, Felding BH, Sinha
SC. SMI-Ribosome inactivating protein conjugates selectively inhibit tumor cell growth. Chem Commun
(Camb). 2017 Apr 11;53(30):4234-4237. doi: 10.1039/c7cc00745k. PubMed PMID: 28357420; PubMed Central
PMCID: PMC6594371.

4) Weber MR, Zuka M, Lorger M, Tschan M, Torbett BE, Zijlstra A, Quigley JP, Staflin K, Eliceiri BP, Krueger JS,
Marchese P, Ruggeri ZM, Felding BH. Activated tumor cell integrin αvβ3 cooperates with platelets to promote
extravasation and metastasis from the blood stream. Thromb Res. 2016 Apr;140 Suppl 1:S27-36. doi:10.1016/S0049-3848(16)30095-0. PubMed PMID: 27067975; PubMed Central PMCID: PMC4888909.

5) Wold ED, Smider VV, Felding BH. Antibody Therapeutics in Oncology. Immunotherapy (Los Angel). 2016
Mar;2(1). Epub 2016 Feb 1. PubMed PMID: 27081677; PubMed Central PMCID: PMC4829403.

6) Wold ED, Axup JY, Felding BH, Smider VV. Fc-Small Molecule Antibody Mimetics. Bioconjug Chem. 2015 Dec
16;26(12):2311-4. doi: 10.1021/acs.bioconjchem.5b00530. Epub 2015 Nov 13. PubMed PMID: 26536496;
PubMed Central PMCID: PMC6667356.

7) Johnson CH, Dejea CM, Edler D, Hoang LT, Santidrian AF, Felding BH, Ivanisevic J, Cho K, Wick EC,
Hechenbleikner EM, Uritboonthai W, Goetz L, Casero RA Jr, Pardoll DM, White JR, Patti GJ, Sears CL, Siuzdak
G. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 2015 Jun 2;21(6):891-7. doi:
10.1016/j.cmet.2015.04.011. Epub 2015 May 7. PubMed PMID: 25959674; PubMed Central PMCID:

8) Kurczy ME, Zhu ZJ, Ivanisevic J, Schuyler AM, Lalwani K, Santidrian AF, David JM, Giddabasappa A, Roberts
AJ, Olivos HJ, O'Brien PJ, Franco L, Fields MW, Paris LP, Friedlander M, Johnson CH, Epstein AA, Gendelman
HE, Wood MR, Felding BH, Patti GJ, Spilker ME, Siuzdak G. Comprehensive bioimaging with fluorinated
nanoparticles using breathable liquids. Nat Commun. 2015 Jan 20;6:5998. doi: 10.1038/ncomms6998. PubMed
PMID: 25601659; PubMed Central PMCID: PMC4454288.

9) Santidrian AF, LeBoeuf SE, Wold ED, Ritland M, Forsyth JS, Felding BH. Nicotinamide
phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in
breast cancer. DNA Repair (Amst). 2014 Nov;23:79-87. doi: 10.1016/j.dnarep.2014.08.006. Epub 2014 Sep
26. PubMed PMID: 25263164; PubMed Central PMCID: PMC4252795.

10) Kularatne SA, Deshmukh V, Ma J, Tardif V, Lim RK, Pugh HM, Sun Y, Manibusan A, Sellers AJ, Barnett RS,
Srinagesh S, Forsyth JS, Hassenpflug W, Tian F, Javahishvili T, Felding-Habermann B, Lawson BR, Kazane SA,
Schultz PG. A CXCR4-targeted site-specific antibody-drug conjugate. Angew Chem Int Ed Engl. 2014 Oct
27;53(44):11863-7. doi: 10.1002/anie.201408103. Epub 2014 Sep 11. PubMed PMID: 25213874; PubMed
Central PMCID: PMC4331128.
bottom of page